AbbVie Inc.(ABBV)NASDAQ
Stock Performance & Returns
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
ABBV | 459.82 B | 73.30x | 10.20% | 9.80% | $3.55 | - | - | 2.71% | $267.47 | $189.40 |
950160.KQ | 1.44 T | - | - | - | - | - | - | - | $149000.00 | $11470.00 |
AMGN | 240.11 B | 27.77x | 9.50% | 22.95% | $15.99 | 91.47% | 4.90 | 2.33% | $447.03 | $262.49 |
950220.KQ | 16.73 B | - | 45.59% | - | - | -61.03% | 0.20 | - | $5465.00 | $1115.00 |
Peer Valuation & Performance Analysis
Peer group analysis for AbbVie Inc. (ABBV) compared to its primary competitors (including 950160.KQ, AMGN, 950220.KQ) reveals distinct metrics. ABBV trades at a valuation premium compared to its competitors, with a P/E ratio of 73.3x versus the peer average of 27.8x (representing a 164% premium). This indicates that the market expects superior growth or commands a quality premium for ABBV. In terms of growth, ABBV's revenue growth of 10.2% lags behind the peer average of 27.5%, indicating potential market share losses or slower industry adoption. Additionally, its net margin of 9.8% is below the peer average of 22.9%, suggesting higher operational costs or lower pricing power relative to peers.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• ABBV ranks #2 in P/E ratio, #2 in revenue growth, and #2 in profit margins
• Average ranking: #2 - 🎯 Top-tier fundamentals relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-09-03 | $264.00 | $264.25 | $257.14 | $260.21 | 2,878,400 | -1.44% |
| 2026-09-02 | $262.70 | $262.97 | $257.70 | $261.72 | 4,225,200 | -0.37% |
| 2026-09-01 | $260.99 | $262.27 | $257.79 | $259.99 | 3,866,100 | -0.38% |
| 2026-08-31 | $254.17 | $258.24 | $252.33 | $256.42 | 4,315,000 | +0.89% |
| 2026-08-28 | $258.67 | $259.00 | $255.08 | $255.48 | 3,224,400 | -1.23% |
| 2026-08-27 | $260.81 | $262.50 | $257.25 | $258.15 | 4,761,900 | -1.02% |
| 2026-08-26 | $264.60 | $265.00 | $260.31 | $262.90 | 3,305,100 | -0.64% |
| 2026-08-25 | $264.50 | $266.91 | $263.03 | $265.79 | 3,671,000 | +0.49% |
| 2026-08-24 | $263.99 | $266.04 | $262.07 | $264.52 | 3,883,600 | +0.20% |
| 2026-08-21 | $260.70 | $266.84 | $260.10 | $264.96 | 5,157,200 | +1.63% |
| 2026-08-20 | $265.69 | $265.93 | $260.48 | $261.83 | 5,228,900 | -1.45% |
| 2026-08-19 | $261.51 | $266.97 | $259.55 | $265.97 | 5,533,800 | +1.71% |
| 2026-08-18 | $253.93 | $259.18 | $252.41 | $258.92 | 5,008,800 | +1.97% |
| 2026-08-17 | $249.49 | $251.49 | $248.31 | $250.33 | 4,648,600 | +0.34% |
| 2026-08-14 | $250.60 | $250.61 | $247.68 | $249.46 | 4,195,000 | -0.45% |
Explore More Analysis for ABBV
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.